Our team is committed to enhancing our understanding of human disease.
Transforming the measurement of disease progression in vivo using noninvasive biosensors.
Bioengineered, tunable sensors that are designed for each protease-mediated disease.
Evolving the way diseases are understood, tracked and treated to accelerate the development of drugs.
Transforming the way diseases are detected, tracked, treated, and understood.
Leveraging the profound advances in engineering, medicine, biotechnology, and machine learning.
We are proud to be members of the pre-eminent Cambridge biotech community.
Transforming the way diseases are detected, tracked, treated, and understood.
No new events at this time.
#ICYMI – CEO Dr. Caroline Loew shares career advice for moving from pharma to #biotech, discusses our response to the pandemic, and outlines our clinical programs with @BioPharmaMike on @DRGInsights’ “Conversations in Healthcare.”
Watch: https://decisionresourcesgroup.com/downloads/glympse-bio-oversubscribed-series-b-funding-amidst-pandemic/
#GlympseBio CEO @CarolineLoew and co-founder @SNBhatia recently spoke with @MIT News about the discovery that led to our platform of synthetic #biosensors and their journey from concept to company.
Read: https://news.mit.edu/2021/faster-tracking-treatment-responses-glympse-bio-0202
Today we announced that Jessica Atkinson has joined the #GlympseBio team as SVP of #businessdevelopment. Her deep industry experience will support our mission to transform disease detection and monitoring. Welcome to the team, Jessica!
Learn more:
https://glympsebio.com/wp-content/uploads/2021/02/Glympse-SVP-of-BD-announcement-FINAL.pdf
#GlympseBio is seeking experienced #Scientists focused on #PeptideSynthesis or High Throughput Screening.
We are continuing to build a strong, values-driven organization focused on our people and rigorously pushing the boundaries. Learn more at http://www.glympsebio.com/careers